(Alliance News) - Novacyt SA said Friday it has now has launched a CE-Mark approved polymerase chain reaction two gene target test for Covid-19, following the release of its single gene target test previously.
In late July, the clinical diagnostics firm launched a single gene test, but a number of countries require a two gene target testing approach for Covid-19. This includes France, Belgium, Croatia, Poland and the UAE.
"The Haute Autorite de Sante, which advises the French government on medical reimbursement, has confirmed to the company that the two gene Covid-19 test will qualify for reimbursement for use by French testing laboratories," Novacyt added.
Novacyt said the two gene test has been confirmed in validation studies undertaken by the company.
Chief Executive Graham Mullis said: "Novacyt continues to demonstrate its ability to rapidly develop new products to address needs within the diagnostics market to support laboratories and clinicians in the ongoing fight against the spread of Covid-19. We remain committed to building on Novacyt's innovative position on a global scale as the demand for Covid-19 testing continues."
Novacyt's single gene target test has been built around "robust design principles" and the selection of a gene target that has "so far demonstrated exceedingly low levels of genetic mutation and variation".
"To date, the gene target has been analysed against 60,256 individual Covid-19 viral sequences and demonstrated 100% detection. The two gene target test for Covid-19 will also be added to this weekly surveillance monitoring programme to demonstrate continued efficacy of the test to diagnose SARS-CoV-2," the company added.
Shares in Novacyt were 3.0% higher in London on Friday morning at 309.00 pence each.
By Paul McGowan; firstname.lastname@example.org
Copyright 2020 Alliance News Limited. All Rights Reserved.